Is EOLS or EVO more undervalued in 2026?

CirclFi compares Evolus, Inc. Common Stock (EOLS) and Evotec SE (EVO) using 13 institutional-grade valuation models. EOLS has a Quality of Company score of 5.9/10 while EVO scores 6.2/10.

Which is a better buy — EOLS or EVO?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do EOLS and EVO valuations compare?

EOLS at $6.57 and EVO at $2.96 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

EOLS vs EVO Valuation Comparison 2026 — Intrinsic Value Analysis

EOLS

Drug Manufacturers - Specialty & Generic

Evolus, Inc. Common Stock

Quality

5.9

out of 10

Value Trap

LOW

Price

$6.57

Last close

Models

10/13

Active

EVO

Drug Manufacturers - Specialty & Generic

Evotec SE

Quality

6.2

out of 10

Value Trap

SAFE

Price

$2.96

Last close

Models

10/13

Active

Model-by-Model Comparison

Model	Type	EOLS Fair Value	EOLS Upside	EVO Fair Value	EVO Upside
Bayesian DCF	Intrinsic	$1.14	-82.6%	$0.22	-92.8%
Earnings Power Value	Intrinsic	$3.70	-30.5%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$1.77	-73.1%	$1.12	-62.0%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for EOLS vs EVO — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

EOLS vs EVO — Which Stock Is More Undervalued?

EVO scores higher with a 6.2/10 quality rating vs EOLS's 5.9/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Evolus, Inc. Common Stock (EOLS) and Evotec SE (EVO) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

EOLS currently trades at $6.57 with a QOC of 5.9/10, while EVO trades at $2.96 with a QOC of 6.2/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).